Teva Pharmaceutical Industries Q2 Adjusted Earnings, Revenue Fall; Raises 2026 Revenue Guidance

MT Newswires Live
07/29

Teva Pharmaceutical Industries (TEVA) reported Q2 adjusted earnings Wednesday of $0.02 per diluted share, compared with $0.66 a year earlier.

Analysts polled by FactSet expected $0.05.

Net revenue for the quarter ended June 30 was $4.14 billion, down from $4.18 billion a year earlier.

Analysts expected $4.02 billion.

The company raised its 2026 revenue guidance to $16.5 billion to $16.85 billion, from its previous outlook of $16.4 billion to $16.8 billion.

Analysts expect $16.52 billion.

Teva reaffirmed its full-year adjusted EPS guidance of $1.91 to $2.11.

Analysts expect $2.02.

Shares of the company were up 5.69% in Wednesday premarket activity.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10